LANTUS
Generic Name for LANTUS
Insulin glargine (recombinant) 100 IU/mL; inj; contains m-cresol.
Legal Classification:
Rx
Manufacturer of LANTUS
Sanofi Aventis
|
Indications for LANTUS
Type 1 diabetes (in adults and children) and type 2 diabetes (in adults) when basal (long-acting) insulin is needed.
Adults and Children:
Give once daily at same time each day; SC inj only. Onset 1.1 hrs, no pronounced peak, duration 24 hrs or longer. <6yrs: not recommended. ≥6yrs: individualize; monitor and adjust as needed. Switching from once-daily NPH or ultralente insulin: initial dose should be the same on a unit-for-unit basis. Switching from twice-daily NPH: reduce initial insulin glargine dose by 20% from previous total NPH dose. Insulin-naive, type 2 diabetics on oral antidiabetic: initially 10 IU; range 2–100 IU.
Precautions for LANTUS
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction. Pregnancy (Cat.C). Nursing mothers.
Interactions for LANTUS
Do not mix or dilute with other insulins. Potentiated by salicylates, MAOIs, alcohol, sulfa drugs, some ACE inhibitors, drugs that inhibit pancreatic function (eg, octreotide). Antagonized by corticosteroids, isoniazid, niacin, thiazides, phenothiazines, sympathomimetics. Variable effects with β-blockers, clonidine, lithium salts, alcohol.
Adverse Reactions for LANTUS
Pain, other inj site reactions, pruritus, rash, hypoglycemia, hypokalemia, lipodystrophy, edema.
How is LANTUS supplied?
Vials (10mL)—1
Cartridges (3mL)—5 (for OptiClik)
Lantus SoloStar pen (3mL)—5 (prefilled, disposable inj device)
Related Disease:
Diabetes mellitus~hyperglycemic agents